about
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era.Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).Predictive models of toxicity in external radiotherapy: dosimetric issues.Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues.Dose-volume effects for normal tissues in external radiotherapy: pelvis.Radiation dose-volume effects in the larynx and pharynx.Reducing rectal injury during external beam radiotherapy for prostate cancer.miRNAs in tumor radiation response: bystanders or participants?Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose-effect.Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects.Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning.miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.Predicting toxicity in radiotherapy for prostate cancer.Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force.Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials."What if…": decisional regret in patients who discontinued active surveillance.Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer.Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model.To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy.Comment on "Objective assessment in digital images of skin erythema caused by radiotherapy" [Med. Phys. 42, 5568-5577 (2015)].Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer.Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study.Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance.Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients.Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy.Long term rectal function after high-dose prostatecancer radiotherapy: results from a prospective cohort study.Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer.Reply from authors re: Laurence Klotz. Active surveillance, quality of life, and cancer-related anxiety. Eur Urol 2013;64:37-9: active surveillance: risk and protective factors for quality of life.NTCP modeling of subacute/late laryngeal edema scored by fiberoptic examination.Feasibility of safe ultra-high (EQD(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy.Long-term biochemical control of prostate cancer after standard or hyper-fractionation: evidence for different outcomes between low-intermediate and high risk patients.Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer.Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study.Editorial Comment to Health-related quality of life after carbon-ion radiotherapy for prostate cancer: a 3-year prospective study.Eleven-year management of prostate cancer patients on active surveillance: what have we learned?First application of a pixel-wise analysis on bladder dose-surface maps in prostate cancer radiotherapy.Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy.Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study.Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial.Understanding urinary toxicity after radiotherapy for prostate cancer: first steps forward.
P50
Q30234489-65F301E5-DAA6-4967-B42E-F026477D3A54Q30968067-64EEEF95-4CC6-49EC-AAD5-1C8F224C011FQ37526771-D5BDF915-173A-4D75-AAFC-654D56091D4CQ37526775-B40F800A-5E8A-47F4-9D96-637E6D34DD94Q37600136-9FEC1308-3321-4D5E-B867-3A46C6FF084CQ37695554-F8689E4D-05C3-4AE1-AD7C-66F51FBEA347Q38106626-A4CE6187-75D0-4ED1-8FBD-96EB9C5CD0B6Q38242941-1F1ECD96-FB20-4D17-A636-20E14DA69A88Q38615852-D60B2D0C-424C-47B1-AA5D-8AE9E47E22F4Q38663923-529F4DBE-4694-430B-B35D-E322ADD75534Q38680195-33591CC1-6030-47E5-A5F7-351F9AD9F571Q38713064-A2E01DDC-733C-401B-97AF-B8D8150254CEQ38805511-4115B367-58B6-428F-9A16-857A3F4F2930Q38813319-7B69DA97-324C-440F-901B-9DE8D4950BFAQ39033358-83713645-6FB0-4D8A-BBCA-D193616635DFQ39311814-1A34F636-0E88-42E7-B0AB-DA41818E9F02Q39445228-78411C48-FE21-4662-9809-AA95BF389689Q39650529-4A32574B-A11D-439C-8688-EAB6E9C5FEDAQ39884923-849FE07A-A129-49FF-96FB-E17601B64166Q40371917-3E97CEF4-9D30-4ADF-BF6F-85789A8D8629Q40799835-B9635061-3771-48E5-B2B2-9417C434A488Q43352411-CDAF5A2D-A5F9-465F-8A7E-88DA55611844Q43438783-8BD05ED3-69D2-42DD-AF09-D4575FE929F7Q43750117-B8A13C6A-3AB7-448C-BD1D-FCCA39929900Q43787924-B601578B-F4EB-460F-B91A-BAA044EFE10BQ43821542-40781EEE-04BE-4FBA-BE4D-6144B373A885Q44046441-6CA617FB-8F49-49F0-AD23-01E68B94EDCCQ44294489-BAA86C98-8996-49B5-8281-3219959FEC3FQ44946932-CCD4AFE5-10C8-4ACE-8A58-355E7FD68327Q45070750-58E65328-31A3-48D2-8C6D-1E5E445058DEQ45081487-19AEE08E-2007-45AC-B0DF-68434F895F39Q45287778-8DD9E8ED-77FF-403A-89D2-CF394A364CEBQ47757232-25F5F02A-6F23-45F0-BE21-545DF5A0A395Q48135904-0F6840E9-99CF-4175-8A62-0E69184207D6Q48632510-DF1610CA-C1F8-4303-B64A-FCF68D495D37Q48845979-84C1499C-51F5-42BB-8A2A-C6FA73E93878Q48882184-85DE836C-8AEF-4651-B433-D629C1680FE3Q48959914-8D459B6B-D5CF-4A3B-BA3F-015BEEBA5237Q50151423-0F9CCB53-32CB-4EBF-8622-715F28C8EC01Q50197960-72E0F1A5-2193-4685-969A-B80CF41B599C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tiziana Rancati
@ast
Tiziana Rancati
@en
Tiziana Rancati
@es
Tiziana Rancati
@nl
type
label
Tiziana Rancati
@ast
Tiziana Rancati
@en
Tiziana Rancati
@es
Tiziana Rancati
@nl
prefLabel
Tiziana Rancati
@ast
Tiziana Rancati
@en
Tiziana Rancati
@es
Tiziana Rancati
@nl
P106
P1153
55244960800
57190091277
P21
P31
P496
0000-0002-7849-603X